Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital in connection with its acquisition of Björn Lundén AB
Mandate

Vinge has advised Main Capital in connection with its acquisition of Björn Lundén AB

July 08, 2021 Employment and Benefits Intellectual Property M&A

Björn Lundén AB, founded in 1987, provides accounting and financial software solutions targeted at accounting firms and SMEs.

Björn Lundén serves over 30,000 companies in the Swedish market and has 120 employees. The company has developed a comprehensive portfolio of solutions and tools for administration, finance, accounting, tax, legal and personnel administration and in addition offers knowledge tools, books and courses in the aforementioned areas.

Vinge’s team consisted of Filip Öhrner, Henrik Borna, Daniel Daun, Lena Westberg, Ellinor Wargenbrant, Nando Basic, Jonathan Hörnblad (M&A), Emelie Svensäter Jerntorp, Karin Gynnerstedt (Employment), Lisa Bourghardt (IP) and Ellinore Boström Andersson.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025